Neurological Biomarkers Market: Product Diversification Remains Key Strategy for Manufacturers: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2025)
- REP-GB-6626
- 2018-04-27
- Category: Healthcare, Pharmaceuticals and Medical devices
- 259 Pages
- Format:
Genomics emerges as the trending biomarker type, and is expected to witness impressive growth
Neurology disorders are affecting major percentage of the global population and it is considered a major cause of disability around the globe. The prevalence of neurological disorders is growing at a very high pace, in which biomarkers are expected play a vital role in better understanding of the disease and development of personalized medicine specific to the patient. There are different types of biomarkers in the market, such as Genomics Biomarker, Proteomics Biomarker, Metabolomics Biomarkers, Imaging Biomarkers, Others. Among these, geonomics biomarker is expected to hold a higher market value reach over US$ 2,700 Mn by the end of 2025.
With the advancements taking place in the healthcare industry and expansion of neurological biomarkers market, new trends are being introduced in the market. A latest trend introduces genomics to the biomarkers market. The process is considered to be an efficient process of examining a disease at the genetic level. It can play major role in the drug development and personalized medicine too. Imaging biomarkers has also come up as one attractive biomarker type, which is expected to witness growth at a high rate in the years coming ahead. Metabolomics biomarkers is also one of these attractive category in the market which is expected to be a lucrative segment in the coming years.
Neurological biomarkers market stands strong in terms of business, as the market demands personalized medicines
Early diagnosis of neurological diseases plays a crucial role in successful management of the disease. Neurological system has limited accessibility and thus, makes diagnosis of the disease a difficult process. Moreover, presently available diagnostic procedures lack sensitivity and specificity for evaluation of disease progression and prognosis. Neurological disorders are diagnosed with cognitive testing, clinical history, structural MRI and neurological examination. However, there are few circumstances wherein identification of specific biomarker is required to understand the diagnosis and treatment of the disease. Biomarker is considered as an indicator in evaluation and measurement of a pathological and physiological process or indicator for pharmacological response to a treatment. Biomarkers are common reference point for diagnosis of disease and play a major role in the development of personalized medicine. There has been significant progress in understanding of onset and development of neurological diseases at the epigenomic and genomic levels. It leads to rapid development of biomarkers in diagnosis of disease with main emphasis in personalized medicine. The growth is expected to take place rapidly, with the requirements of personalized medicines in the coming years.
The market is expected to be stay active also with the increase in research initiatives taking place. There is a huge demand for identifying and validating biomarkers from a large number of population and conducting the research process with the help of this method. It is anticipated to be major factor marking the growth of neurological biomarkers market.
Heterogeneity of Disease turns out to be a stout hindrance in the growth of neurological biomarkers market
In case of heterogeneity, the same disease phenotype is produced with multiple interrelated processes and it increases the difficulty of discovery of biomarkers in degenerative diseases. Such cases can be misleading and increases the complications of the detection and analysis process. It leads to confusion between abnormal and normal health conditions. The clinical symptoms of one disease may be identified by number of heterogeneous Omics variations. Such cases can tone down the expectations of people from neurological biomarkers process and also hamper the growth of its market globally.
Global Healthcare Services Sector Outlook
There is growing consensus among healthcare providers that the current fee-for-services payment mechanism needs an overhaul. While fee-for-services is the pervasive method of billing patients, alternative processes, such as capitation and pay-for-performance are also being considered. We anticipate fee-for-services to be supplemented by capitation and pay-for-performance in the future. In addition to charging patients for screening and doctor visits, pay-for-performance can lead to higher quality of care, as other essential tasks will also be billed. It may lead to an increase in healthcare costs, with the promise that quality of care will go up.
The healthcare system is in a phase where access to capital is constantly diminishing. Big spends are rare and there is increasing uncertainty among borrowers about their ability to repay loans and funding. Healthcare institutions are either postponing large capital-intensive projects or allocating resources to specialty areas that offer a high ROI. Cash-constraints will result into an increase in mergers and acquisitions and lead to fundraising from healthcare providers. However, as only a select few will qualify for an acquisition or funding, the effects of cash-crunch will be palpable in this sector.
Healthcare providers and insurers are aware of the rapidly increasingly population and their growing healthcare needs. The impact is more palpable in the U.S. and Japan – important markets in terms of their standing in the global healthcare market. Providers and insurers are strategizing to tap into the available opportunities in this demographic. Baby boomers around the globe are actively taking charge of their health. Smartphone remains the primary source of information-seeking for this segment. With over 70,000 websites and hundreds of apps disseminating information, providers and insurers will focus on strengthening their digital presence to effectively target this demographic.
Research Methodology
FMI utilizes robust methodology and approach to arrive at market size and related projections. The research methodology for this report is based on 3 dimensional model. We conduct about 45-60 min duration detailed interviews with product manufacturers; apart from this we also collect market feedback from industry experts. To validate this data, we interact with senior panel members having more than 10 years of experience in relevant field. The panel members help in validating the findings and fill the gaps if any. In addition, we leverage on our existing pool of information, paid database and other valid information sources available in public domain. Usually industry interactions extend to more than 50+ interviews from market participants across the value chain.
Data Collection
FMI collects data from secondary sources including company annual reports, association publications, industry presentations, white papers, and company press releases apart from these we leverage over paid database subscriptions and industry magazines to collect market information and developments in exhaustive manner. After being done with desk research, detailed questionnaire and discussion guide is formulated to initiate primary research with key industry personnel; the discussion aims at collecting key insights, growth perspectives, prevalent market trends and quantitative insights including market size and competition developments. Both of these research approaches help us in arriving at base year numbers and market hypothesis.
Data Validation
In this phase, FMI validates the data using macro and micro economic factors. For instance, growth in electricity consumption, industry value added, other industry factors, economic performance, growth of top players and sector performance is closely studied to arrive at precise estimates and refine anomalies if any.
Data Analysis and Projection
Data analysis and projections were made based on proprietary research frameworks and statistical analysis, which was further validated from industry participants. These frameworks include Y-o-Y growth projections, macro-economic factor performance, market attractiveness analysis, key financial ratios, and others.
For public companies we capture the data from company website, annual reports, and investor presentations, paid databases. While for privately held companies, we try to gather information from the paid databases (like Factiva) and based on the information we gather from databases we estimate revenue for the companies. In addition, the team tries to establish primary contact with the companies in order to validate the assumptions or to gather quality inputs.
Standard Report Structure
-
Executive Summary
-
Market Definition
-
Macro-economic analysis
-
Parent Market Analysis
-
Market Overview
-
Forecast Factors
-
Segmental Analysis and Forecast
-
Regional Analysis
-
Competition Analysis
Target Audience
-
Physicians
-
Surgeons
-
Pathology In charge
-
Procurement Manager
-
Laboratory Technicians
-
Hospital Accountants
-
Independent Consultants
-
Government Authorities
Market Taxonomy
By Type
-
Genomics Biomarker
-
Proteomics Biomarker
-
Metabolomics Biomarkers
-
Imaging Biomarkers
-
Others
By Application
-
Alzheimer's Disease
-
Parkinson's Disease
-
Huntington's Disease
-
Schizophrenia
-
Depression
-
Multiple Sclerosis
-
Spinal Muscular Atrophy
By End User
-
Research Organizations, Pharma & Biotech Companies
-
Clinical Diagnostics
By region
-
North America
-
Latin America
-
Europe
-
Asia-Pacific
-
Middle East & Africa
Neurological Biomarkers Market Reports - Table of Contents
1. Executive Summary
A gist of the report, highlighting the key takeaways
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
A definition of Neurological Biomarkers and related market taxonomy
2.1. Market Definition
2.2. Market Taxonomy
2.3. Neurological Biomarkers Market Overview
2.4. Company and Chief Analyst Credentials
3. Market View Point
Tracking the market scenario, with key inferences drawn from historical data, current trends, and future prospects
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
4. Market Background
4.1. Technology Evolution and List of Neurological Biomarkers
4.2. List of Growth Hacking Manufacturers
5. Industry Structure
5.1. Marketing and Distribution Strategies
5.2. Market Size by Tiers
6. Macroeconomic Assumptions
7. Global Economic Outlook
7.1. Gross Domestic Product by Region & Country, 2006 – 2021
7.2. Disease Outlook
8. North America Neurological Biomarkers Market Analysis 2012–2016 and Forecast 2017–2025
Market forecast and analysis in the U.S. and Canada
8.1. Introduction
8.2. Key Regulations
8.3. Regional Market Dynamics
8.3.1. Drivers
8.3.2. Restraints
8.3.3. Trends
8.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
8.4.1. U.S.
8.4.2. Canada
8.5. Market Size (US$ Mn) Forecast By Country, 2017–2025
8.5.1. U.S.
8.5.2. Canada
8.6. Historical Market Size (US$ Mn) Analysis By Type, 2012–2016
8.6.1. Genomics Biomarker
8.6.2. Proteomic Biomarker
8.6.3. Metabolomics Biomarker
8.6.4. Imaging biomarkers
8.6.5. Others
8.7. Market Size (US$ Mn) Forecast By Type, 2017–2025
8.7.1. Genomics Biomarker
8.7.2. Proteomic Biomarker
8.7.3. Metabolomics Biomarker
8.7.4. Imaging biomarkers
8.7.5. Others
8.8. Historical Market Size (US$ Mn) Analysis By Application, 2012-2016
8.8.1. Alzheimer’s disease
8.8.2. Parkinson’s disease
8.8.3. Huntington’s disease
8.8.4. Schizophrenia
8.8.5. Depression
8.8.6. Multiple Sclerosis
8.8.7. Spinal Muscular Atrophy (SMA)
8.9. Market Size (US$ Mn) Forecast By Application, 2017-2025
8.9.1. Alzheimer’s disease
8.9.2. Parkinson’s disease
8.9.3. Huntington’s disease
8.9.4. Schizophrenia
8.9.5. Depression
8.9.6. Multiple Sclerosis
8.9.7. Spinal Muscular Atrophy (SMA)
8.10. Historical Market Size (US$ Mn) Analysis By End User, 2012-2016
8.10.1. Research Institutes and Diagnostic Centers
8.10.2. Hospitals
8.11. Market Size (US$ Mn) Forecast By End User, 2017-2025
8.11.1. Research Institutes and Diagnostic Centers
8.11.2. Hospitals
8.12. Market Attractiveness Analysis
8.12.1. By Country
8.12.2. By Type
8.12.3. By Application
8.12.4. By End User
8.13. Key Representative Market Participants
8.14. Key Participants Market Presence (Intensity Map)
9. Latin America Neurological Biomarkers Market Analysis 2012–2016 and Forecast 2017–2025
Market forecast and analysis in Brazil, Mexico, Argentina and Rest of Latin America
9.1. Introduction
9.2. Key Regulations
9.3. Regional Market Dynamics
9.3.1. Drivers
9.3.2. Restraints
9.3.3. Trends
9.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Argentina
9.4.4. Rest of Latin America
9.5. Market Size (US$ Mn) Forecast By Country, 2017–2025
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Argentina
9.5.4. Rest of Latin America
9.6. Historical Market Size (US$ Mn) Analysis By Type, 2012–2016
9.6.1. Genomics Biomarker
9.6.2. Proteomic Biomarker
9.6.3. Metabolomics Biomarker
9.6.4. Imaging biomarkers
9.6.5. Others
9.7. Market Size (US$ Mn) Forecast By Type, 2017–2025
9.7.1. Genomics Biomarker
9.7.2. Proteomic Biomarker
9.7.3. Metabolomics Biomarker
9.7.4. Imaging biomarkers
9.7.5. Others
9.8. Historical Market Size (US$ Mn) Analysis By Application, 2012-2016
9.8.1. Alzheimer’s disease
9.8.2. Parkinson’s disease
9.8.3. Huntington’s disease
9.8.4. Schizophrenia
9.8.5. Depression
9.8.6. Multiple Sclerosis
9.8.7. Spinal Muscular Atrophy (SMA)
9.9. Market Size (US$ Mn) Forecast By Application, 2017-2025
9.9.1. Alzheimer’s disease
9.9.2. Parkinson’s disease
9.9.3. Huntington’s disease
9.9.4. Schizophrenia
9.9.5. Depression
9.9.6. Multiple Sclerosis
9.9.7. Spinal Muscular Atrophy (SMA)
9.10. Historical Market Size (US$ Mn) Analysis By End User, 2012-2016
9.10.1. Research Institutes and Diagnostic Centers
9.10.2. Hospitals
9.11. Market Size (US$ Mn) Forecast By End User, 2017-2025
9.11.1. Research Institutes and Diagnostic Centers
9.11.2. Hospitals
9.12. Market Attractiveness Analysis
9.12.1. By Country
9.12.2. By Type
9.12.3. By Application
9.12.4. By End User
9.13. Key Representative Market Participants
9.14. Key Participants Market Presence (Intensity Map)
10. Europe Neurological Biomarkers Market Analysis 2012–2016 and Forecast 2017–2025
Market forecast and analysis in Germany, France, Italy, Spain, U.K., Russia, and rest of Europe
10.1. Introduction
10.2. Key Regulations
10.3. Regional Market Dynamics
10.3.1. Drivers
10.3.2. Restraints
10.3.3. Trends
10.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
10.4.1. Germany
10.4.2. France
10.4.3. U.K.
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Rest of Europe
10.5. Market Size (US$ Mn) Forecast By Country, 2017–2025
10.5.1. Germany
10.5.2. France
10.5.3. U.K.
10.5.4. Spain
10.5.5. Italy
10.5.6. Russia
10.5.7. Rest of Europe
10.6. Historical Market Size (US$ Mn) Analysis By Type, 2012–2016
10.6.1. Genomics Biomarker
10.6.2. Proteomic Biomarker
10.6.3. Metabolomics Biomarker
10.6.4. Imaging biomarkers
10.6.5. Others
10.7. Market Size (US$ Mn) Forecast By Type, 2017–2025
10.7.1. Genomics Biomarker
10.7.2. Proteomic Biomarker
10.7.3. Metabolomics Biomarker
10.7.4. Imaging biomarkers
10.7.5. Others
10.8. Historical Market Size (US$ Mn) Analysis By Application, 2012-2016
10.8.1. Alzheimer’s disease
10.8.2. Parkinson’s disease
10.8.3. Huntington’s disease
10.8.4. Schizophrenia
10.8.5. Depression
10.8.6. Multiple Sclerosis
10.8.7. Spinal Muscular Atrophy (SMA)
10.9. Market Size (US$ Mn) Forecast By Application, 2017-2025
10.9.1. Alzheimer’s disease
10.9.2. Parkinson’s disease
10.9.3. Huntington’s disease
10.9.4. Schizophrenia
10.9.5. Depression
10.9.6. Multiple Sclerosis
10.9.7. Spinal Muscular Atrophy (SMA)
10.10. Historical Market Size (US$ Mn) Analysis By End User, 2012-2016
10.10.1. Research Institutes and Diagnostic Centers
10.10.2. Hospitals
10.11. Market Size (US$ Mn) Forecast By End User, 2017-2025
10.11.1. Research Institutes and Diagnostic Centers
10.11.2. Hospitals
10.12. Market Attractiveness Analysis
10.12.1. By Country
10.12.2. By Type
10.12.3. By Application
10.12.4. By End User
10.13. Key Representative Market Participants
10.14. Key Participants Market Presence (Intensity Map)
11. Asia Pacific Neurological Biomarkers Market Analysis 2012–2016 and Forecast 2017–2025
Market forecast and analysis in China, India, Japan, ASEAN, Australia & New Zealand, and Rest of Asia Pacific
11.1. Introduction
11.2. Key Regulations
11.3. Regional Market Dynamics
11.3.1. Drivers
11.3.2. Restraints
11.3.3. Trends
11.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. Australia and New Zealand
11.4.5. ASEAN
11.4.6. Rest of Asia Pacific
11.5. Market Size (US$ Mn) Forecast By Country, 2017–2025
11.5.1. China
11.5.2. India
11.5.3. Japan
11.5.4. Australia and New Zealand
11.5.5. ASEAN
11.5.6. Rest of Asia Pacific
11.6. Historical Market Size (US$ Mn) Analysis By Type, 2012–2016
11.6.1. Genomics Biomarker
11.6.2. Proteomic Biomarker
11.6.3. Metabolomics Biomarker
11.6.4. Imaging biomarkers
11.6.5. Others
11.7. Market Size (US$ Mn) Forecast By Type, 2017–2025
11.7.1. Genomics Biomarker
11.7.2. Proteomic Biomarker
11.7.3. Metabolomics Biomarker
11.7.4. Imaging biomarkers
11.7.5. Others
11.8. Historical Market Size (US$ Mn) Analysis By Application, 2012-2016
11.8.1. Alzheimer’s disease
11.8.2. Parkinson’s disease
11.8.3. Huntington’s disease
11.8.4. Schizophrenia
11.8.5. Depression
11.8.6. Multiple Sclerosis
11.8.7. Spinal Muscular Atrophy (SMA)
11.9. Market Size (US$ Mn) Forecast By Application, 2017-2025
11.9.1. Alzheimer’s disease
11.9.2. Parkinson’s disease
11.9.3. Huntington’s disease
11.9.4. Schizophrenia
11.9.5. Depression
11.9.6. Multiple Sclerosis
11.9.7. Spinal Muscular Atrophy (SMA)
11.10. Historical Market Size (US$ Mn) Analysis By End User, 2012-2016
11.10.1. Research Institutes and Diagnostic Centers
11.10.2. Hospitals
11.11. Market Size (US$ Mn) Forecast By End User, 2017-2025
11.11.1. Research Institutes and Diagnostic Centers
11.11.2. Hospitals
11.12. Market Attractiveness Analysis
11.12.1. By Country
11.12.2. By Type
11.12.3. By Application
11.12.4. By End User
11.13. Key Representative Market Participants
11.14. Key Participants Market Presence (Intensity Map)
12. MEA Neurological Biomarkers Market Analysis 2012–2016 and Forecast 2017–2025
Market forecast and analysis in GCC, South Africa, and Rest of MEA
12.1. Introduction
12.2. Key Regulations
12.3. Regional Market Dynamics
12.3.1. Drivers
12.3.2. Restraints
12.3.3. Trends
12.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
12.4.1. GCC Countries
12.4.2. South Africa
12.4.3. Rest of MEA
12.5. Market Size (US$ Mn) Forecast By Country, , 2017–2025
12.5.1. GCC Countries
12.5.2. South Africa
12.5.3. Rest of MEA
12.6. Historical Market Size (US$ Mn) Analysis By Type, 2012–2016
12.6.1. Genomics Biomarker
12.6.2. Proteomic Biomarker
12.6.3. Metabolomics Biomarker
12.6.4. Imaging biomarkers
12.6.5. Others
12.7. Market Size (US$ Mn) Forecast By Type, 2017–2025
12.7.1. Genomics Biomarker
12.7.2. Proteomic Biomarker
12.7.3. Metabolomics Biomarker
12.7.4. Imaging biomarkers
12.7.5. Others
12.8. Historical Market Size (US$ Mn) Analysis By Application, 2012-2016
12.8.1. Alzheimer’s disease
12.8.2. Parkinson’s disease
12.8.3. Huntington’s disease
12.8.4. Schizophrenia
12.8.5. Depression
12.8.6. Multiple Sclerosis
12.8.7. Spinal Muscular Atrophy (SMA)
12.9. Market Size (US$ Mn) Forecast By Application, 2017-2025
12.9.1. Alzheimer’s disease
12.9.2. Parkinson’s disease
12.9.3. Huntington’s disease
12.9.4. Schizophrenia
12.9.5. Depression
12.9.6. Multiple Sclerosis
12.9.7. Spinal Muscular Atrophy (SMA)
12.10. Historical Market Size (US$ Mn) Analysis By End User, 2012-2016
12.10.1. Research Institutes and Diagnostic Centers
12.10.2. Hospitals
12.11. Market Size (US$ Mn) Forecast By End User, 2017-2025
12.11.1. Research Institutes and Diagnostic Centers
12.11.2. Hospitals
12.12. Market Attractiveness Analysis
12.12.1. By Country
12.12.2. By Type
12.12.3. By Application
12.12.4. By End User
12.13. Key Representative Market Participants
12.14. Key Participants Market Presence (Intensity Map)
13. Forecast Factors: Relevance and Impact
14. Forecast Assumptions
A glossary of assumption and acronyms used in the report
15. Competition Landscape
Profile of some of the key market players, with specific focus on business and strategy
15.1. Competition Intensity Mapping By Market Taxonomy
15.2. Competition Dashboard
15.3. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
15.3.1. Quanterix
15.3.2. Myriad RBM
15.3.3. QIAGEN
15.3.4. ADx NeuroSciences NV
15.3.5. Merck KGaA
15.3.6. Euroimmun
15.3.7. Thermo Fisher Scientific
15.3.8. BioCrypton
15.3.9. ACOBIOM
15.3.10. Banyan Biomarkers, Inc.
15.3.11. Olink Biosciences
15.3.12. BioAgilytix
16. Global Neurological Biomarkers Market Analysis 2012–2016 and Forecast 2017–2025, By Region
A detailed, region-wise assessment, providing projections on market growth in key regions
16.1. Introduction / Key Findings
16.2. Historical Market Size (US$ Mn) Analysis By Region, 2012-2016
16.2.1. North America
16.2.2. Latin America
16.2.3. Europe
16.2.4. Asia Pacific
16.2.5. MEA
16.3. Market Size (US$ Mn) Forecast By Region, 2017-2025
16.3.1. North America
16.3.2. Latin America
16.3.3. Europe
16.3.4. Asia Pacific
16.3.5. MEA
16.4. Market Attractiveness Analysis By Region
17. Global Neurological Biomarkers Market Analysis 2012–2016 and Forecast 2017–2025, By Type
Classification of neurological biomarkers into Types; highlighting historical trends, current market value, and future projections on the basis of key segments
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis By Type, 2012–2016
17.2.1. Genomics Biomarker
17.2.2. Proteomic Biomarker
17.2.3. Metabolomics Biomarker
17.2.4. Imaging biomarkers
17.2.5. Others
17.3. Market Size (US$ Mn) Forecast By Type, 2017–2025
17.3.1. Genomics Biomarker
17.3.2. Proteomic Biomarker
17.3.3. Metabolomics Biomarker
17.3.4. Imaging biomarkers
17.3.5. Others
17.4. Key Trends / Developments
17.5. Market Attractiveness Analysis By Type
18. Global Neurological Biomarkers Market Analysis 2012–2016 and Forecast 2017–2025, By Application
Classification based on application; highlighting historical trends, current market value, and future projections on the basis of key segments
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Analysis By Application, 2012-2016
18.2.1. Alzheimer’s disease
18.2.2. Parkinson’s disease
18.2.3. Huntington’s disease
18.2.4. Schizophrenia
18.2.5. Depression
18.2.6. Multiple Sclerosis
18.2.7. Spinal Muscular Atrophy (SMA)
18.3. Market Size (US$ Mn) Forecast By Application, 2017-2025
18.3.1. Alzheimer’s disease
18.3.2. Parkinson’s disease
18.3.3. Huntington’s disease
18.3.4. Schizophrenia
18.3.5. Depression
18.3.6. Multiple Sclerosis
18.3.7. Spinal Muscular Atrophy (SMA)
18.4. Key Trends / Developments
18.5. Market Attractiveness Analysis By Application
19. Global Neurological Biomarkers Market Analysis 2012–2016 and Forecast 2017–2025, By End User
Assessment of End Users for neurological biomarkers; highlighting historical trends, current market value, and future projections on the basis of key segments
19.1. Introduction
19.2. Historical Market Size (US$ Mn) Analysis By End User, 2012-2016
19.2.1. Research Institutes and Diagnostic Centers
19.2.2. Hospitals
19.3. Market Size (US$ Mn) Forecast By End User, 2017-2025
19.3.1. Research Institutes and Diagnostic Centers
19.3.2. Hospitals
19.4. Key Trends / Developments
19.5. Market Attractiveness Analysis By End User
20. Global Neurological Biomarkers Market Analysis 2012–2016 and Forecast 2017–2025
Tracking the market scenario, with key inferences drawn from historical data, current trends, and future prospects
20.1. Market Size and Y-o-Y Growth
20.2. Absolute $ Opportunity
21. Research Methodology
Neurological Biomarkers Market Reports - List of Tables
Table 01 : North America Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
Table 02 : North America Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Type
Table 03 : North America Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Application
Table 04 : North America Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By End User
Table 05 : Latin America Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
Table 06 : Latin America Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Type
Table 07 : Latin America Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Application
Table 08 : Latin America Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By End User
Table 09 : Europe Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
Table 10 : Europe Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Type
Table 11 : Europe Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Application
Table 12 : Europe Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By End User
Table 13 : Asia Pacific Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
Table 14 : Asia Pacific Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Type
Table 15 : Asia Pacific Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Application
Table 16 : Asia Pacific Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By End User
Table 17 : Middle East & Africa Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
Table 18 : Middle East & Africa Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Type
Table 19 : Middle East & Africa Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Application
Table 20 : Middle East & Africa Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By End User
Table 21 : Global Neurological Biomarkers Market Size (US$ Mn) 2012–2016 and Forecast 2017-2025 By Region,
Table 22 : Global Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Type
Table 23 : Global Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Application
Table 24 : Global Neurological Biomarkers Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By End User
Neurological Biomarkers Market Reports - List of Figures
Figure 01 : Global Neurological Biomarkers Market Split By Type (2017)
Figure 02 : Global Neurological Biomarkers Market Split By Application (2017)
Figure 03 : Global Neurological Biomarkers Market Split By End User (2017)
Figure 04 : Global Neurological Biomarkers Market Split By Region (2017)
Figure 05 : North America Neurological Biomarkers Market Value Share (%) By Type (2017)
Figure 06 : North America Neurological Biomarkers Market Value Share (%) By Application (2017)
Figure 07 : North America Neurological Biomarkers Market Value Share (%) By End User (2017)
Figure 08 : North America Neurological Biomarkers Market Value Share (%) By Country (2017)
Figure 09 : North America Neurological Biomarkers Market Value (US$ Mn) & Forecast 2017 & 2025
Figure 10 : North America Neurological Biomarkers Market Size Analysis, 2012–2016
Figure 11 : North America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 12 : North America Neurological Biomarkers Market Size Analysis, 2012–2016, By Genomics Biomarker
Figure 13 : North America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Genomics Biomarker
Figure 14 : North America Neurological Biomarkers Market Size Analysis, 2012–2016, By Proteomics Biomarkers
Figure 15 : North America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Proteomics Biomarkers
Figure 16 : North America Neurological Biomarkers Market Size Analysis, 2012–2016, By Metabolomics Biomarkers
Figure 17 : North America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Metabolomics Biomarkers
Figure 18 : North America Neurological Biomarkers Market Size Analysis, 2012–2016, By Imaging Biomarkers
Figure 19 : North America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Imaging Biomarkers
Figure 20 : North America Neurological Biomarkers Market Size Analysis, 2012–2016, By Others
Figure 21 : North America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Others
Figure 22 : North America Neurological Biomarkers Market Size Analysis, 2012–2016, By Alzheimer's Disease
Figure 23 : North America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Alzheimer's Disease
Figure 24 : North America Neurological Biomarkers Market Size Analysis, 2012–2016, By Parkinson's Disease
Figure 25 : North America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Parkinson's Disease
Figure 26 : North America Neurological Biomarkers Market Size Analysis, 2012–2016, By Foot & Huntington's Disease
Figure 27 : North America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Foot & Huntington's Disease
Figure 28 : North America Neurological Biomarkers Market Size Analysis, 2012–2016, By Schizophrenia
Figure 29 : North America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Schizophrenia
Figure 30 : North America Neurological Biomarkers Market Size Analysis, 2012–2016, By Foot & Depression
Figure 31 : North America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Depression
Figure 32 : North America Neurological Biomarkers Market Size Analysis, 2012–2016, By Multiple Sclerosis
Figure 33 : North America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Multiple Sclerosis
Figure 34 : North America Neurological Biomarkers Market Size Analysis, 2012–2016, By Spinal Muscular Atrophy
Figure 35 : North America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Spinal Muscular Atrophy
Figure 36 : North America Neurological Biomarkers Market Attractiveness Analysis, By Country
Figure 37 : North America Neurological Biomarkers Market Attractiveness Analysis, By Type
Figure 38 : North America Neurological Biomarkers Market Attractiveness Analysis, By Application
Figure 39 : North America Neurological Biomarkers Market Attractiveness Analysis, By End User
Figure 40 : Latin America Neurological Biomarkers Market Value Share (%) By Type (2017)
Figure 41 : Latin America Neurological Biomarkers Market Value Share (%) By Application (2017)
Figure 42 : Latin America Neurological Biomarkers Market Value Share (%) By End User (2017)
Figure 43 : Latin America Neurological Biomarkers Market Value Share (%) By Country (2017)
Figure 44 : Latin America Neurological Biomarkers Market Value (US$ Mn) & Forecast 2017 & 2025
Figure 45 : Latin America Neurological Biomarkers Market Size Analysis, 2012–2016
Figure 46 : Latin America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 47 : Latin America Neurological Biomarkers Market Size Analysis, 2012–2016, By Genomics Biomarker
Figure 48 : Latin America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Genomics Biomarker
Figure 49 : Latin America Neurological Biomarkers Market Size Analysis, 2012–2016, By Proteomics Biomarkers
Figure 50 : Latin America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Proteomics Biomarkers
Figure 51 : Latin America Neurological Biomarkers Market Size Analysis, 2012–2016, By Metabolomics Biomarkers
Figure 52 : Latin America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Metabolomics Biomarkers
Figure 53 : Latin America Neurological Biomarkers Market Size Analysis, 2012–2016, By Imaging Biomarkers
Figure 54 : Latin America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Imaging Biomarkers
Figure 55 : Latin America Neurological Biomarkers Market Size Analysis, 2012–2016, By Others
Figure 56 : Latin America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Others
Figure 57 : Latin America Neurological Biomarkers Market Size Analysis, 2012–2016, By Alzheimer's Disease
Figure 58 : Latin America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Alzheimer's Disease
Figure 59 : Latin America Neurological Biomarkers Market Size Analysis, 2012–2016, By Parkinson's Disease
Figure 60 : Latin America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Parkinson's Disease
Figure 61 : Latin America Neurological Biomarkers Market Size Analysis, 2012–2016, By Foot & Huntington's Disease
Figure 62 : Latin America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Foot & Huntington's Disease
Figure 63 : Latin America Neurological Biomarkers Market Size Analysis, 2012–2016, By Schizophrenia
Figure 64 : Latin America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Schizophrenia
Figure 65 : Latin America Neurological Biomarkers Market Size Analysis, 2012–2016, By Foot & Depression
Figure 66 : Latin America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Depression
Figure 67 : Latin America Neurological Biomarkers Market Size Analysis, 2012–2016, By Multiple Sclerosis
Figure 68 : Latin America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Multiple Sclerosis
Figure 69 : Latin America Neurological Biomarkers Market Size Analysis, 2012–2016, By Spinal Muscular Atrophy
Figure 70 : Latin America Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Spinal Muscular Atrophy
Figure 71 : Latin America Neurological Biomarkers Market Attractiveness Analysis, By Country
Figure 72 : Latin America Neurological Biomarkers Market Attractiveness Analysis, By Type
Figure 73 : Latin America Neurological Biomarkers Market Attractiveness Analysis, By Application
Figure 74 : Latin America Neurological Biomarkers Market Attractiveness Analysis, By End User
Figure 75 : Europe Neurological Biomarkers Market Value Share (%) By Type (2017)
Figure 76 : Europe Neurological Biomarkers Market Value Share (%) By Application (2017)
Figure 77 : Europe Neurological Biomarkers Market Value Share (%) By End User (2017)
Figure 78 : Europe Neurological Biomarkers Market Value Share (%) By Country (2017)
Figure 79 : Europe Neurological Biomarkers Market Value (US$ Mn) & Forecast 2017 & 2025
Figure 80 : Europe Neurological Biomarkers Market Size Analysis, 2012–2016
Figure 81 : Europe Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 82 : Europe Neurological Biomarkers Market Size Analysis, 2012–2016, By Genomics Biomarker
Figure 83 : Europe Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Genomics Biomarker
Figure 84 : Europe Neurological Biomarkers Market Size Analysis, 2012–2016, By Proteomics Biomarkers
Figure 85 : Europe Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Proteomics Biomarkers
Figure 86 : Europe Neurological Biomarkers Market Size Analysis, 2012–2016, By Metabolomics Biomarkers
Figure 87 : Europe Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Metabolomics Biomarkers
Figure 88 : Europe Neurological Biomarkers Market Size Analysis, 2012–2016, By Imaging Biomarkers
Figure 89 : Europe Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Imaging Biomarkers
Figure 90 : Europe Neurological Biomarkers Market Size Analysis, 2012–2016, By Others
Figure 91 : Europe Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Others
Figure 92 : Europe Neurological Biomarkers Market Size Analysis, 2012–2016, By Alzheimer's Disease
Figure 93 : Europe Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Alzheimer's Disease
Figure 94 : Europe Neurological Biomarkers Market Size Analysis, 2012–2016, By Parkinson's Disease
Figure 95 : Europe Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Parkinson's Disease
Figure 96 : Europe Neurological Biomarkers Market Size Analysis, 2012–2016, By Foot & Huntington's Disease
Figure 97 : Europe Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Foot & Huntington's Disease
Figure 98 : Europe Neurological Biomarkers Market Size Analysis, 2012–2016, By Schizophrenia
Figure 99 : Europe Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Schizophrenia
Figure 100 : Europe Neurological Biomarkers Market Size Analysis, 2012–2016, By Foot & Depression
Figure 101 : Europe Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Depression
Figure 102 : Europe Neurological Biomarkers Market Size Analysis, 2012–2016, By Multiple Sclerosis
Figure 103 : Europe Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Multiple Sclerosis
Figure 104 : Europe Neurological Biomarkers Market Size Analysis, 2012–2016, By Spinal Muscular Atrophy
Figure 105 : Europe Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Spinal Muscular Atrophy
Figure 106 : Europe Neurological Biomarkers Market Attractiveness Analysis, By Country
Figure 107 : Europe Neurological Biomarkers Market Attractiveness Analysis, By Type
Figure 108 : Europe Neurological Biomarkers Market Attractiveness Analysis, By Application
Figure 109 : Europe Neurological Biomarkers Market Attractiveness Analysis, By End User
Figure 110 : Asia Pacific Neurological Biomarkers Market Value Share (%) By Type (2017)
Figure 111 : Asia Pacific Neurological Biomarkers Market Value Share (%) By Application (2017)
Figure 112 : Asia Pacific Neurological Biomarkers Market Value Share (%) By End User (2017)
Figure 113 : Asia Pacific Neurological Biomarkers Market Value Share (%) By Country (2017)
Figure 114 : Asia Pacific Neurological Biomarkers Market Value (US$ Mn) & Forecast 2017 & 2025
Figure 115 : Asia Pacific Neurological Biomarkers Market Size Analysis, 2012–2016
Figure 116 : Asia Pacific Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 117 : Asia Pacific Neurological Biomarkers Market Size Analysis, 2012–2016, By Genomics Biomarker
Figure 118 : Asia Pacific Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Genomics Biomarker
Figure 119 : Asia Pacific Neurological Biomarkers Market Size Analysis, 2012–2016, By Proteomics Biomarkers
Figure 120 : Asia Pacific Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Proteomics Biomarkers
Figure 121 : Asia Pacific Neurological Biomarkers Market Size Analysis, 2012–2016, By Metabolomics Biomarkers
Figure 122 : Asia Pacific Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Metabolomics Biomarkers
Figure 123 : Asia Pacific Neurological Biomarkers Market Size Analysis, 2012–2016, By Imaging Biomarkers
Figure 124 : Asia Pacific Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Imaging Biomarkers
Figure 125 : Asia Pacific Neurological Biomarkers Market Size Analysis, 2012–2016, By Others
Figure 126 : Asia Pacific Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Others
Figure 127 : Asia Pacific Neurological Biomarkers Market Size Analysis, 2012–2016, By Alzheimer's Disease
Figure 128 : Asia Pacific Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Alzheimer's Disease
Figure 129 : Asia Pacific Neurological Biomarkers Market Size Analysis, 2012–2016, By Parkinson's Disease
Figure 130 : Asia Pacific Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Parkinson's Disease
Figure 131 : Asia Pacific Neurological Biomarkers Market Size Analysis, 2012–2016, By Foot & Huntington's Disease
Figure 132 : Asia Pacific Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Foot & Huntington's Disease
Figure 133 : Asia Pacific Neurological Biomarkers Market Size Analysis, 2012–2016, By Schizophrenia
Figure 134 : Asia Pacific Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Schizophrenia
Figure 135 : Asia Pacific Neurological Biomarkers Market Size Analysis, 2012–2016, By Foot & Depression
Figure 136 : Asia Pacific Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Depression
Figure 137 : Asia Pacific Neurological Biomarkers Market Size Analysis, 2012–2016, By Multiple Sclerosis
Figure 138 : Asia Pacific Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Multiple Sclerosis
Figure 139 : Asia Pacific Neurological Biomarkers Market Size Analysis, 2012–2016, By Spinal Muscular Atrophy
Figure 140 : Asia Pacific Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Spinal Muscular Atrophy
Figure 141 : Asia Pacific Neurological Biomarkers Market Attractiveness Analysis, By Country
Figure 142 : Asia Pacific Neurological Biomarkers Market Attractiveness Analysis, By Type
Figure 143 : Asia Pacific Neurological Biomarkers Market Attractiveness Analysis, By Application
Figure 144 : Asia Pacific Neurological Biomarkers Market Attractiveness Analysis, By End User
Figure 145 : Middle East & Africa Neurological Biomarkers Market Value Share (%) By Type (2017)
Figure 146 : Middle East & Africa Neurological Biomarkers Market Value Share (%) By Application (2017)
Figure 147 : Middle East & Africa Neurological Biomarkers Market Value Share (%) By End User (2017)
Figure 148 : Middle East & Africa Neurological Biomarkers Market Value Share (%) By Country (2017)
Figure 149 : Middle East & Africa Neurological Biomarkers Market Value (US$ Mn) & Forecast 2017 & 2025
Figure 150 : Middle East & Africa Neurological Biomarkers Market Size Analysis, 2012–2016
Figure 151 : Middle East & Africa Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 152 : Middle East & Africa Neurological Biomarkers Market Size Analysis, 2012–2016, By Genomics Biomarker
Figure 153 : Middle East & Africa Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Genomics Biomarker
Figure 154 : Middle East & Africa Neurological Biomarkers Market Size Analysis, 2012–2016, By Proteomics Biomarkers
Figure 155 : Middle East & Africa Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Proteomics Biomarkers
Figure 156 : Middle East & Africa Neurological Biomarkers Market Size Analysis, 2012–2016, By Metabolomics Biomarkers
Figure 157 : Middle East & Africa Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Metabolomics Biomarkers
Figure 158 : Middle East & Africa Neurological Biomarkers Market Size Analysis, 2012–2016, By Imaging Biomarkers
Figure 159 : Middle East & Africa Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Imaging Biomarkers
Figure 160 : Middle East & Africa Neurological Biomarkers Market Size Analysis, 2012–2016, By Others
Figure 161 : Middle East & Africa Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Others
Figure 162 : Middle East & Africa Neurological Biomarkers Market Size Analysis, 2012–2016, By Alzheimer's Disease
Figure 163 : Middle East & Africa Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Alzheimer's Disease
Figure 164 : Middle East & Africa Neurological Biomarkers Market Size Analysis, 2012–2016, By Parkinson's Disease
Figure 165 : Middle East & Africa Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Parkinson's Disease
Figure 166 : Middle East & Africa Neurological Biomarkers Market Size Analysis, 2012–2016, By Foot & Huntington's Disease
Figure 167 : Middle East & Africa Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Foot & Huntington's Disease
Figure 168 : Middle East & Africa Neurological Biomarkers Market Size Analysis, 2012–2016, By Schizophrenia
Figure 169 : Middle East & Africa Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Schizophrenia
Figure 170 : Middle East & Africa Neurological Biomarkers Market Size Analysis, 2012–2016, By Foot & Depression
Figure 171 : Middle East & Africa Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Depression
Figure 172 : Middle East & Africa Neurological Biomarkers Market Size Analysis, 2012–2016, By Multiple Sclerosis
Figure 173 : Middle East & Africa Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Multiple Sclerosis
Figure 174 : Middle East & Africa Neurological Biomarkers Market Size Analysis, 2012–2016, By Spinal Muscular Atrophy
Figure 175 : Middle East & Africa Neurological Biomarkers Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025, By Spinal Muscular Atrophy
Figure 176 : Middle East & Africa Neurological Biomarkers Market Attractiveness Analysis, By Country
Figure 177 : Middle East & Africa Neurological Biomarkers Market Attractiveness Analysis, By Type
Figure 178 : Middle East & Africa Neurological Biomarkers Market Attractiveness Analysis, By Application
Figure 179 : Middle East & Africa Neurological Biomarkers Market Attractiveness Analysis, By End User
Figure 180 : Global Neurology Biomarkers Market Share Analysis (%) By Region, 2017 & 2025
Figure 181 : Global Neurology Biomarkers Market Y-o-Y Growth (%) By Region, 2017–2025
Figure 182 : Global Neurological Biomarkers Market Attractiveness Analysis By Region, 2017–2025
Figure 183 : Global Neurology Biomarkers Market Share Analysis (%) By Type, 2017 & 2025
Figure 184 : Global Neurology Biomarkers Market Y-o-Y Growth (%) By Type, 2017–2025
Figure 185 : Global Neurological Biomarkers Market Attractiveness Analysis By Type, 2017–2025
Figure 186 : Global Neurology Biomarkers Market Share Analysis (%) By Application, 2017 & 2025
Figure 187 : Global Neurology Biomarkers Market Y-o-Y Growth (%) By Application, 2017–2025
Figure 188 : Global Neurological Biomarkers Market Attractiveness Analysis By Application, 2017–2025
Figure 189 : Global Neurology Biomarkers Market Share Analysis (%) By End User, 2017 & 2025
Figure 190 : Global Neurology Biomarkers Market Y-o-Y Growth (%) By End User, 2017–2025
Figure 191 : Global Neurological Biomarkers Market Attractiveness Analysis By End User, 2017–2025
Figure 192 : Global Neurological Biomarkers Market Value Analysis and Forecast, 2016–2025 (US$ Mn)
Figure 193 : Global Neurological Biomarkers Market Absolute $ Opportunity (US$ Mn), 2012–2016
Figure 194 : Global Neurological Biomarkers Market Absolute $ Opportunity (US$ Mn), 2016–2025